Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/10495

3,4-Dihydrocoumarin: Target Organs and Levels of Evidence for TR-423

Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CASRN 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review Date Route/Exposure Levels Study Laboratory
3,4-Dihydrocoumarin
119-84-6
06/23/1992 Gavage
R: 0,150,300,600, M: 0,200,400,800 MG/KG/50 PER GROUP
American Biogenics Corp (Bioassay Systems)

Levels of Evidence

Male Rats: Some Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Tubular Cell: ADENOMA 0/50 1/48 0/47 2/50, STEP SECTIONS 1/50 0/48 3/47 5/50
May Have Been Related
  • Kidney Transitional Cell: CARCINOMA 0/50 0/48 0/47 2/50
Non-Neoplastic Lesions
  • FORESTOMACH: ULCER; HYPERPLASIA; INFLAMMATION
  • PARATHYROID GLAND: HYPERPLASIA
  • KIDNEY: TUBULAR CELL HYPERPLASIA; INCREASED SEVERITY OF NEPHROPATHY
Female Rats: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • KIDNEY: INCREASED SEVERITY OF NEPHROPATHY
Male Mice: No Evidence
Female Mice: Some Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 10/51 20/50 22/50 20/52 OR CARCINOMA 3/51 2/50 4/50 6/52 COMBINED 13/51 21/50 25/50 24/52


Chemical (Study Title)
CASRN
Peer Review Date Route/Exposure Levels Study Laboratory
3,4-Dihydrocoumarin
119-84-6
Gavage
R: 0,75,1200, M: 0,100,1600 MG/KG/10 PER GROUP
International Research & Development Corp.

Levels of Evidence: None